CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab
We examined outcomes of 244 patients with marginal zone lymphoma (MZL) diagnosed in 2010-2020, of which 25 (10%) expressed CD5. CD5 expression was present in 22% of splenic, 8% of nodal, and 5% of extranodal MZL, and showed frequent blood/bone marrow involvement, elevated lactate dehydrogenase, and TP53 deletions. CD5 expression was not associated with progression-free or overall survival, but it conferred a significantly higher risk of histologic transformation (22% versus 4% at 5 years, p = 0.002). Among patients receiving first-line rituximab monotherapy, CD5 expression was associated with lower response rate (30% versus 77%, p = 0.006), PFS (25% versus 45% at 3 years, p = 0.003) and OS (44% versus 77%, p = 0.010), whereas CD5 status did not significantly affect outcomes of patients receiving bendamustine with rituximab (P for interaction = 0.012 for progression-free survival). CD5-positive MZL may have a propensity to leukemic dissemination, histologic transformation, and may derive benefit from first-line bendamustine/rituximab rather than rituximab alone.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
---|---|
Enthalten in: |
Leukemia & lymphoma - 63(2022), 1 vom: 01. Jan., Seite 31-42 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hsu, Andrew [VerfasserIn] |
---|
Links: |
---|
Themen: |
4F4X42SYQ6 |
---|
Anmerkungen: |
Date Completed 07.03.2022 Date Revised 07.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/10428194.2021.1973670 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330104799 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330104799 | ||
003 | DE-627 | ||
005 | 20231225210555.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/10428194.2021.1973670 |2 doi | |
028 | 5 | 2 | |a pubmed24n1100.xml |
035 | |a (DE-627)NLM330104799 | ||
035 | |a (NLM)34467833 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hsu, Andrew |e verfasserin |4 aut | |
245 | 1 | 0 | |a CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.03.2022 | ||
500 | |a Date Revised 07.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a We examined outcomes of 244 patients with marginal zone lymphoma (MZL) diagnosed in 2010-2020, of which 25 (10%) expressed CD5. CD5 expression was present in 22% of splenic, 8% of nodal, and 5% of extranodal MZL, and showed frequent blood/bone marrow involvement, elevated lactate dehydrogenase, and TP53 deletions. CD5 expression was not associated with progression-free or overall survival, but it conferred a significantly higher risk of histologic transformation (22% versus 4% at 5 years, p = 0.002). Among patients receiving first-line rituximab monotherapy, CD5 expression was associated with lower response rate (30% versus 77%, p = 0.006), PFS (25% versus 45% at 3 years, p = 0.003) and OS (44% versus 77%, p = 0.010), whereas CD5 status did not significantly affect outcomes of patients receiving bendamustine with rituximab (P for interaction = 0.012 for progression-free survival). CD5-positive MZL may have a propensity to leukemic dissemination, histologic transformation, and may derive benefit from first-line bendamustine/rituximab rather than rituximab alone | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CD5 expression | |
650 | 4 | |a Marginal zone lymphoma | |
650 | 4 | |a bendamustine | |
650 | 4 | |a rituximab | |
650 | 7 | |a Rituximab |2 NLM | |
650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
650 | 7 | |a Bendamustine Hydrochloride |2 NLM | |
650 | 7 | |a 981Y8SX18M |2 NLM | |
700 | 1 | |a Kurt, Habibe |e verfasserin |4 aut | |
700 | 1 | |a Zayac, Adam S |e verfasserin |4 aut | |
700 | 1 | |a Olszewski, Adam J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 63(2022), 1 vom: 01. Jan., Seite 31-42 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
773 | 1 | 8 | |g volume:63 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:31-42 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2021.1973670 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 63 |j 2022 |e 1 |b 01 |c 01 |h 31-42 |